Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ALDX
- CUSIP: N/A
- Web: www.aldeyra.com
Capitalization:- Market Cap: $141.36 million
- Outstanding Shares: 6,245,000
Average Prices:- 50 Day Moving Avg: $4.93
- 200 Day Moving Avg: $4.79
- 52 Week Range: $3.80 - $11.90
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.34
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.54 per share
- Price / Book: 4.94
Profitability:- EBIDTA: ($19,820,000.00)
- Return on Equity: -80.41%
- Return on Assets: -70.58%
Debt:- Debt-to-Equity Ratio: 0.04%
- Current Ratio: 12.48%
- Quick Ratio: 12.48%
Misc:- Average Volume: 612,786 shs.
- Beta: 0.33
- Short Ratio: 2.46
Frequently Asked Questions for Aldeyra Therapeutics (NASDAQ:ALDX)
What is Aldeyra Therapeutics' stock symbol?
Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."
How were Aldeyra Therapeutics' earnings last quarter?
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) announced its earnings results on Tuesday, August, 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.37) by $0.02. View Aldeyra Therapeutics' Earnings History.
When will Aldeyra Therapeutics make its next earnings announcement?
Where is Aldeyra Therapeutics' stock going? Where will Aldeyra Therapeutics' stock price be in 2017?
4 brokerages have issued 1 year target prices for Aldeyra Therapeutics' shares. Their forecasts range from $14.00 to $27.00. On average, they expect Aldeyra Therapeutics' share price to reach $18.75 in the next year. View Analyst Ratings for Aldeyra Therapeutics.
What are analysts saying about Aldeyra Therapeutics stock?
Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:
- 1. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (8/17/2017)
- 2. Cowen and Company analysts commented, "On its 4Q call, ALDX announced the Feb start of the planned ADX-102 Ph2b allergic." (3/31/2017)
Who are some of Aldeyra Therapeutics' key competitors?
Some companies that are related to Aldeyra Therapeutics include Madrigal Pharmaceuticals (MDGL), Oxford BioMedica plc (OXB), Athersys (ATHX), Stemline Therapeutics (STML), Immune Design Corp. (IMDZ), Arrowhead Pharmaceuticals (ARWR), Ardelyx (ARDX), Tocagen (TOCA), DURECT Corporation (DRRX), Kura Oncology (KURA), Circassia Pharmaceuticals PLC (CIR), uniQure N.V. (QURE), Chimerix (CMRX), Pieris Pharmaceuticals (PIRS), Faron Pharmaceuticals Oy (FARN), ObsEva SA (OBSV), Mast Therapeutics (SVRA) and Ovid Therapeutc (OVID).
Who are Aldeyra Therapeutics' key executives?
Aldeyra Therapeutics' management team includes the folowing people:
- Todd Brady M.D., President, Chief Executive Officer, Director
- Stephen J. Tulipano CPA, Chief Financial Officer, Treasurer
- Scott L Young, Chief Operating Officer
- David J. Clark M.D., Chief Medical Officer
- Ben Bronstein M.D., Director
- Jesse I. Treu Ph.D., Director
- Richard H. Douglas Ph.D., Independent Director
- Martin J. Joyce, Independent Director
- Gary M. Phillips M.D., Independent Director
Who owns Aldeyra Therapeutics stock?
Aldeyra Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (26.49%), Sphera Funds Management LTD. (14.03%), Vanguard Group Inc. (4.88%), Hikari Power Ltd (1.73%) and Virtu KCG Holdings LLC (0.36%). Company insiders that own Aldeyra Therapeutics stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.
Who sold Aldeyra Therapeutics stock? Who is selling Aldeyra Therapeutics stock?
Who bought Aldeyra Therapeutics stock? Who is buying Aldeyra Therapeutics stock?
Aldeyra Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Hikari Power Ltd, Virtu KCG Holdings LLC and Vanguard Group Inc.. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.
How do I buy Aldeyra Therapeutics stock?
Shares of Aldeyra Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aldeyra Therapeutics' stock price today?
One share of Aldeyra Therapeutics stock can currently be purchased for approximately $7.60.
MarketBeat Community Rating for Aldeyra Therapeutics (NASDAQ ALDX)MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Aldeyra Therapeutics (NASDAQ:ALDX)Earnings History by Quarter for Aldeyra Therapeutics (NASDAQ ALDX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | | ($0.41) | | | | | N/A |  |
| 8/8/2017 | Q2 2017 | ($0.37) | ($0.35) | | | View | Listen | |
| 5/15/2017 | Q1 2017 | ($0.33) | ($0.37) | | | View | N/A | |
| 3/30/2017 | Q4 2016 | ($0.66) | ($0.36) | | | View | N/A | |
| 11/14/2016 | Q316 | ($0.39) | ($0.38) | | | View | N/A | |
| 8/10/2016 | Q216 | ($0.44) | ($0.41) | | | View | Listen | |
| 5/9/2016 | Q116 | ($0.50) | ($0.51) | | | View | N/A | |
| 11/12/2015 | Q315 | ($0.29) | ($0.35) | | | View | Listen | |
| 8/11/2015 | Q215 | ($0.35) | ($0.27) | | | View | Listen | |
| 5/13/2015 | Q115 | ($0.39) | ($0.32) | | | View | Listen | |
| 4/14/2015 | | ($0.39) | ($0.31) | | | View | N/A | |
| 11/10/2014 | Q314 | ($0.32) | ($0.36) | | | View | N/A | |
| 8/4/2014 | Q214 | ($0.53) | ($1.56) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Aldeyra Therapeutics (NASDAQ:ALDX)Current Year EPS Consensus Estimate: $-1.67 EPS
Next Year EPS Consensus Estimate: $-1.75 EPS
Dividend History for Aldeyra Therapeutics (NASDAQ:ALDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aldeyra Therapeutics (NASDAQ:ALDX)Insider Ownership Percentage: 28.40%
Institutional Ownership Percentage: 49.09%
Insider Trades by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/19/2017 | Life Sciences Maste Perceptive | Major Shareholder | Buy | 200,000 | $7.25 | $1,450,000.00 | |
| 6/30/2017 | Life Sciences Maste Perceptive | Major Shareholder | Buy | 296,007 | $4.60 | $1,361,632.20 | |
| 2/17/2017 | Martin Joseph Joyce | Director | Buy | 4,444 | $4.50 | $19,998.00 | |
| 2/17/2017 | Stephen J Tulipano | CFO | Buy | 3,333 | $4.50 | $14,998.50 | |
| 2/17/2017 | Todd C Brady | Insider | Buy | 22,223 | $4.50 | $100,003.50 | |
| 2/14/2017 | Perceptive Advisors Llc | Major Shareholder | Buy | 893,025 | $4.50 | $4,018,612.50 | |
| 5/26/2016 | Perceptive Advisors Llc | Major Shareholder | Buy | 700,000 | $5.00 | $3,500,000.00 | |
| 10/26/2015 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $6.46 | $323,000.00 | |
| 10/22/2015 | Perceptive Advisors Llc | Major Shareholder | Buy | 18,020 | $6.47 | $116,589.40 | |
| 10/20/2015 | Perceptive Advisors Llc | Major Shareholder | Buy | 37,145 | $6.39 | $237,356.55 | |
| 8/7/2014 | Martin Joseph Joyce | Director | Buy | 1,000 | $3.95 | $3,950.00 | |
| 8/6/2014 | C. Boyd Clarke | Director | Buy | 3,000 | $3.69 | $11,070.00 | |
| 5/7/2014 | C. Boyd Clarke | Director | Buy | 12,500 | $8.00 | $100,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Aldeyra Therapeutics (NASDAQ:ALDX)
Latest Headlines for Aldeyra Therapeutics (NASDAQ:ALDX)
| Source: |
|
| Date | Headline |
|---|
 | Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - September 22 at 2:47 PM |
 | Life Sciences Maste Perceptive Purchases 200,000 Shares of Aldeyra Therapeutics, Inc. (ALDX) Stock
www.americanbankingnews.com - September 21 at 10:26 AM |
| Aldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 3:39 PM |
 | Mid-Morning Market Update: Markets Edge Higher; AutoZone Earnings Top Expectations - Benzinga
www.benzinga.com - September 19 at 3:44 PM |
 | Aldeyra Therapeutics (ALDX) Prices 3.45M Common Stock Offering at $7.25/Share - StreetInsider.com
www.streetinsider.com - September 19 at 3:43 PM |
 | Aldeyra Therapeutics: Secondary Offering Clears Key Overhang - Seeking Alpha
seekingalpha.com - September 19 at 3:43 PM |
| Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 19 at 3:43 PM |
| Aldeyra Therapeutics: Transitioning Into A Promising Late-Stage Story - Seeking Alpha
seekingalpha.com - September 18 at 9:10 PM |
| Aldeyra Finally Gets The Recognition It Deserves - Seeking Alpha
seekingalpha.com - September 18 at 9:10 PM |
| Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 18 at 4:08 PM |
| Brokerages Anticipate Aldeyra Therapeutics, Inc. (ALDX) Will Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - September 17 at 12:30 AM |
| Aldeyra Spikes On 'Significant Improvements' In Midstage Dry Eye Study - Seeking Alpha
seekingalpha.com - September 16 at 3:35 PM |
| Today's Research Reports on Trending Tickers: Aldeyra Therapeutics and Arrowhead Pharmaceuticals
finance.yahoo.com - September 15 at 4:04 PM |
| Aldeyra Therapeutics' (ALDX) "Outperform" Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - September 14 at 9:08 AM |
| Pre-Open Stock Movers 09/13: (SNAK) (ALDX) (JWN) Higher; (DCTH) (AMRK) (WDC) Lower (more...)
www.streetinsider.com - September 14 at 2:55 AM |
| Aldeyra Therapeutics (ALDX) Presents On Dry Eye Disease Phase 2a Results - Slideshow
seekingalpha.com - September 14 at 2:55 AM |
 | Aldeyra Therapeutics Inc. (ALDX) Jumped To A 5-Month High On Study Results
www.rttnews.com - September 13 at 4:53 PM |
| Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session
finance.yahoo.com - September 13 at 4:53 PM |
| Aldeyra Therapeutics, Inc. (ALDX) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - September 13 at 8:36 AM |
| Aldeyra Therapeutics, Inc. (ALDX) Upgraded at ValuEngine
www.americanbankingnews.com - September 12 at 11:56 PM |
 | Mid-Afternoon Market Update: Sage Therapeutics Drops After Brexanolone Drug Fails Phase III Testing; Aldeyra Therapeutics Shares Gain
www.nasdaq.com - September 12 at 8:59 PM |
| Aldeyra Therapeutics Inc. (ALDX) Has Jumped To A 9-Month High On Study Results
www.rttnews.com - September 12 at 8:59 PM |
| Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial
finance.yahoo.com - September 12 at 3:57 PM |
| Aldeyra Therapeutics' stock soars after positive results of dry eye disease treatment
finance.yahoo.com - September 12 at 3:57 PM |
| Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers
finance.yahoo.com - September 12 at 3:56 PM |
| Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Dry Eye Disease Phase 2a Clinical Trial
finance.yahoo.com - September 11 at 4:34 PM |
| Aldeyra Therapeutics, Inc. (ALDX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 6 at 2:50 AM |
| Aldeyra Therapeutics, Inc. (ALDX) Expected to Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - August 29 at 12:10 PM |
| Aldeyra Therapeutics, Inc. (ALDX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 17 at 6:50 PM |
| Aldeyra Therapeutics, Inc. (ALDX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 10 at 8:28 PM |
| Aldeyra Therapeutics, Inc. (ALDX) Issues Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - August 9 at 4:34 PM |
| Aldeyra Therapeutics Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 3:38 PM |
| Aldeyra Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference
finance.yahoo.com - August 3 at 3:47 PM |
| Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2017 Financial Results
finance.yahoo.com - August 1 at 4:42 PM |
| Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to Release Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM |
| Zacks: Brokerages Anticipate Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Will Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - July 21 at 10:20 PM |
| Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2a Clinical Trial
finance.yahoo.com - July 18 at 5:11 PM |
| Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Major Shareholder Life Sciences Maste Perceptive Buys 296,007 Shares
www.americanbankingnews.com - July 5 at 7:06 PM |
| Zacks: Brokerages Expect Aldeyra Therapeutics, Inc. (ALDX) Will Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - June 27 at 6:23 PM |
| Aldeyra Therapeutics to Present Novel Data on the Anti-Inflammatory Mechanism and Activity of ADX-102 at the World Congress on Inflammation 2017 Annual Meeting
finance.yahoo.com - June 19 at 3:30 PM |
| Canaccord Genuity Analysts Give Aldeyra Therapeutics, Inc. (ALDX) a $12.00 Price Target
www.americanbankingnews.com - June 15 at 11:20 PM |
| Keep An Eye On ALDX Today
www.rttnews.com - June 15 at 1:31 AM |
| Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing
finance.yahoo.com - June 14 at 3:29 PM |
| Aldeyra Therapeutics stock drops 16% after mid-stage trial miss
finance.yahoo.com - June 14 at 3:29 PM |
| Aldeyra Stumbles Over Mid-Stage Clinical Results
finance.yahoo.com - June 14 at 3:29 PM |
| Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial
finance.yahoo.com - June 13 at 8:29 PM |
| Aldeyra Therapeutics (ALDX) Says First Patient Enrolled in Dry Eye Disease Phase 2a Trial
www.streetinsider.com - June 8 at 9:09 PM |
| Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial
finance.yahoo.com - June 6 at 9:51 AM |
| Aldeyra Therapeutics (ALDX) Enters $20M ATM Offering Agreement
www.streetinsider.com - June 3 at 2:38 AM |
| Zacks: Analysts Anticipate Aldeyra Therapeutics Inc (ALDX) to Post -$0.41 Earnings Per Share
www.americanbankingnews.com - June 1 at 2:22 PM |
Aldeyra Therapeutics (ALDX) Chart for Friday, September, 22, 2017
